Nexalin Technology Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
/ 
Frequently asked questions
To buy Nexalin Technology Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Nexalin Technology Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Nexalin Technology Inc. is NXL:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Nexalin Technology Inc. has its primary listing on NASDAQ (Small cap). You can trade Nexalin Technology Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Nexalin Technology Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Nexalin Technology Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Nexalin Technology Inc..